TO THE EDITOR:
The position paper on racial and ethnic disparities in health care (1) certainly has considerable merit and contains many recommendations that are very proper and appropriate. However, I feel compelled to comment on the section titled "Minorities in Medical School," since I vehemently disagree with it. Indeed, I am appalled, embarrassed, disappointed, and saddened that the American College of Physicians would take such an inappropriate position. While the other positions and recommendations in the article are certainly valid, admissions to medical school should be based on merit and achievement and should reflect quality. They should not be affected by ethnic issues, which need to be addressed at multiple levels before admission to medical school. It should not matter whether an entire class is male or female or black or white, as long as the best applicants for admission are selected. Indeed, "the best man for the job may be a woman." One or two generations ago, few women were admitted to medical school, and now approximately 50% of many classes are women, not because of their sex but because they are the best applicants for the positions.
Finally, I would reiterate my comments from a previous letter to another publication (2) , suggesting that none of us, male or female or black or white, would recommend affirmative action for commercial airline pilots; we want quality and competency, not race, creed, or color.
My thoughts are really only common sense (however, common sense is really not common).
IN RESPONSE:
Regarding Dr. Nassar's comments, the College views the elimination of disparities in health care as one of many important steps needed to decrease the number of the uninsured and increase access to good-quality health care. Lack of insurance does not exclusively affect minorities. Although minorities are at greater risk for being uninsured, white persons make up 75% of the uninsured population in the United States (1) . Lack of insurance is more a reflection of socioeconomics, including the financial ability of employers to supply insurance and of employees to purchase insurance. Lowincome Americans are at the highest risk for being uninsured: More than one third of the poor and more than one quarter of the nearpoor lack coverage (2) . The College's proposal to increase access to care therefore targets the nation's most vulnerable individuals as a first step toward providing coverage for all (3) . By expanding income requirements for Medicaid and converting the State Children's Health Insurance Program (SCHIP) into a federal-state entitlement program, the plan aims to extend coverage to low-income individuals by strengthening the safety net.
In response to Dr. Cohen, the College continues to support the consideration of race and ethnicity in determining admissions to institutions of higher education. Health professions have not kept pace with the nation's changing demographics. While racial concordance between health care provider and patient is not a necessity, increased diversity in the health workforce can improve the overall health of the nation by enhancing quality and making the patient feel less isolated and more accepted by the health care system.
Affirmative action ensures that minorities are accurately represented in health professions. Eighty percent fewer minorities would have been accepted into U.S. medical schools in 1996 without affirmative action, a rate similar to that of the 1960s (4). In 2004, 1 year after the U.S. Supreme Court upheld affirmative action in university admissions, the number of black and Hispanic persons who entered medical school increased by 2.5% and almost 8%, respectively (5).
Affirmative action enhances diversity in the profession. This causes people to challenge stereotypes; shapes the quality of medical education, research, and care; and increases access to care. The College supports additional interventions throughout the educational pipeline, including strengthened math and science curricula, tutoring and mentoring programs, loan forgiveness programs, and efforts to increase faculty diversity. Overall, a health care system that mirrors the racial and ethnic makeup of the general population will be more capable of meeting the needs of individuals from diverse backgrounds. Analogous to a staff-model health maintenance organization, the VA benefits from having enterprise-wide electronic medical records, employed physicians with restrictive formularies, and direct control over the practice patterns of those physicians through mandated use of practice guidelines. Commercial managed care plans rely on contracted physicians who are generally in private practice, are unlikely to have electronic records, and are much less under the control of the plan. To draw comparisons between these 2 widely disparate types of managed care organizations and conclude that a federally sponsored national health care organization would be superior to managed care is disingenuous. Kerr and colleagues should have compared both models with a completely unmanaged fee-for-service setting, for which data are available. The VA system is a managed care organization in every sense. If the VA clinical outcomes are indeed better, it is probably because of the higher-intensity care management afforded by having greater control over employed physicians. The more accurate conclusion is that managed care improves diabetes quality measures more than unmanaged care and that these improvements are related to the intensity of management afforded by the specific managed-care model. Kerr and colleagues' attempt to discredit managed care actually makes the case for it. IN RESPONSE: As we mentioned in our article, the VA's transformation was indeed based on many managed care principles, and as the largest integrated health care system in the United States, it could, as Dr. Patmas suggests, be considered the nation's largest managed care organization. This is precisely what makes the comparison between diabetes care quality in commercial managed care and in the VA so interesting-one can begin to think about the elements unique to the VA that may have further enhanced quality beyond the strategies espoused in the commercial managed care plans. While comparisons between VA and nonmanaged care systems had previously been published (1), our study was, to our knowledge, the first to compare diabetes quality in the VA with that in high-performing commercial managed care organizations. The plans that participated in the Translating Research into Action for Diabetes (TRIAD) study reflected a full spectrum of practice arrangements, including group and staff-model plans with employed physicians, network model plans with large and small contracted group practices, and individual practice associations. As we noted in our article, when the VA system was compared only with the TRIAD study staff-model plans that used electronic medical records, the findings were essentially the same. The authors of our article have a variety of affiliations, including academic institutions, the VA, and managed care organizations. Indeed, we made no attempt to discredit managed care, which performed very well in our study by all commercial standards. Rather, we called for further research to examine how specific organizational factors, such as the intensity of management, influence care quality and for a deeper understanding of which VA investments may be worth translating to commercial managed care. These types of investigations could improve care quality for many patients with diabetes, whether they receive care in federally sponsored or commercial managed care organizations. 
Charles

Limitations of Virtual Colonoscopy
TO THE EDITOR: Pickhardt and colleagues (1) reported that the miss rate for optical colonoscopy (OC) using virtual colonoscopy (VC) was 12% for polyps 10 mm or greater. This and another paper (2) , where these data originated, shed a very favorable light on VC. As co-investigators in the original study and as gastroenterologists, we would like to point out as-yet-unadvertised aspects of these data to provide a more balanced view of VC. Sensitivity and specificity of VC were high in the original study, but VC had a high false-positive rate of 51.1% (95% CI, 40.4% to 61.7%) (47 of 92) for polyps 10 mm or greater and a low positive predictive value of 48.9% (CI, 38.3% to 59.6%) (45 of 92). For polyps 6 mm or greater, the false-positive rate was 59.3% (CI, 54.1% to 64.4%) (217 of 366) with a positive predictive value of 40.7% (CI, 35.7% to 45.9%) (149 of 366) (2). Thus, if patients with polyps 6 mm or greater on VC were referred for OC, 217 would have potentially received OC unnecessarily. Van Gelder and associates (3) reported similar results with VC: false-positive rates of 41% for polyps 10 mm or greater and 64% for polyps 6 mm or greater. The OC miss rate in that study was 17% for polyps 10 mm or greater.
Admittedly, sensitivity and specificity are more important for tests that screen for low-prevalence disease. However, when a test is expensive and uncomfortable and risks high radiation exposure, the issues become more complex. From the patient's and the endoscopist's perspectives, the high false-positive rates and low positive predictive values seen with VC are problematic, since findings on this test may represent low likelihood of true disease. Thus, patients' anxiety about the results and the extra time spent by endoscopists may not be warranted. This high false-positive rate also reduces the benefit of preselection. These concerns have been more than academic at our institution, where we have been using VC for screening.
Ultimately, despite criticism that VC may be inaccurate, with sensitivity and specificity as low as 55% for polyps 10 mm or greater (4), we believe it has a role in screening when done correctly. However, results may vary with different software, protocols, and technologies. Thus, when VC is applied broadly, it may not work as well as originally promised, and its shortcomings may not be apparent from initial reports. We must understand the limitations of VC before we embrace it as the standard of care for clinical practice. Table 3 of our original publication (1) and are therefore not a revelation. Although our more recent study actually focused on OC and not VC performance, I would nonetheless like to respond to Drs. Hwang and Wong's comments about the positive predictive value of VC. It is important to note that these numbers reflect only adenomatous polyps. Since neither VC nor OC is specific for polyp histology, perhaps it is unfair to count nonadenomatous lesions (such as hyperplastic polyps) as false-positive results. By applying the same logic, the positive predictive values of OC at 10-and 6-mm thresholds were 66.7% (48 of 72) and 65.9% (168 of 255), respectively. This lack of specificity for OC is often overlooked, but in our study, OC-detected "lesions" as large as 8 cm corresponded to normal mucosa (3) . When all polyps are considered positive results, regardless of histology, the positive predictive value for VC increases by about 20% (67.4% [62 of 92] and 58.5% [214 of 366] at the 10-and 6-mm thresholds, respectively). Furthermore, because OC is an imperfect reference standard (even with segmental unblinding), it is likely that additional "false-positive" results on VC actually represent false-negative results on OC. It should be understood that a relatively low positive predictive value and high negative predictive value are expected when evaluating a test in a low-prevalence setting, despite excellent sensitivity and specificity. Although the performance of VC in our screening trial was very encouraging, this rapidly evolving technology will no doubt continue to improve. Recent VC software advances and refinement of our colon preparation now allow more rapid and probably more accurate interpretation (4). Because of our proven methods, the VC program at the University of Wisconsin recently became the first to receive widespread reimbursement for VC screening from third-party payers (5). Initial experience with our first 400 patients indicates that the continued improvements are paying off: The positive predictive values are 83.3% for adenomas 10 mm or greater to date (100% for all lesions Ն 10 mm) and 66.7% for adenomas 6 mm or greater (90.5% for all lesions Ն 6 mm). Only 5% of all patients who had VC have been referred for same-day OC, in part because we offer patients with lesions 6 to 9 mm the option of noninvasive VC surveillance. This referral rate bodes well for cost-effectiveness. Finally, with regard to the relative advantages and disadvantages of VC versus OC, I argue that the latter incurs more expense, discomfort, and risk.
CLINICAL OBSERVATION
Prolonged Coagulopathy Related to Superwarfarin Overdose
TO THE EDITOR: Background: Superwarfarin poisoning is a growing public health problem in the United States and affects people of all ages, primarily children (1) . Physicians must have a high index of suspicion for superwarfarin exposure when patients have unexplained coagulopathy resistant to vitamin K replacement and fresh frozen plasma.
Case Report: A 50-year-old man with a history of depression presented with hematuria, epistaxis, widespread ecchymosis of the skin, and guaiac-positive stool. He reported ingesting warfarin with suicidal intent. His hemoglobin level was 48 g/L (normal range, 137 to 165 g/L), his prothrombin time was greater than 50 seconds (normal range, 11.5 to 14.3 seconds), and his activated partial thromboplastin time was more than 150 seconds (normal range, 21 to 37 seconds). The international normalized ratio (INR) was too high to be reported. Results of liver function tests were normal. The patient received blood transfusions, fresh frozen plasma, and vitamin K. He was discharged 6 days later with a hemoglobin level of 122 g/L, a prothrombin time of 14.7 seconds, an INR of 1.26, and an activated partial thromboplastin time of 50 seconds. Vitamin K was withdrawn. A week later, the patient returned with epistaxis and bruising of the skin. His hemoglobin level had decreased to 7.9 g/L (prothrombin time Ͼ200 seconds), an INR of 397.5, and an activated partial thromboplastin time of 95.3 seconds. The patient reported that he had taken no additional warfarin since discharge. However, he confirmed that the anticoagulant he had ingested 4 weeks ago was d-CON (Reckitt Benckiser, Wayne, New Jersey), not warfarin. This superwarfarin rodenticide has brodifacoum as the active compound. The patient was again treated with fresh frozen plasma, blood transfusion, and vitamin K. This time, however, he was discharged while receiving oral vitamin K, 100 mg/d. Vitamin K dose was to be tapered over the next 2 months, depending on weekly prothrombin time and INR.
Discussion: Superwarfarins were developed in the 1970s to overcome warfarin resistance in rats. These long acting, fat-soluble anticoagulants are colorless, tasteless, odorless compounds. Superwarfarins are 100 times more potent than warfarin (2) and can kill a mouse in 1 compared with 21 days. The half-life of superwarfarin varies from 16 to 69 days compared with 37 hours for warfarin (2, 3) . Brodifacoum, a 4-hydroxycoumarin derivative, is the most commonly used superwarfarin in the United States (1). It is primarily absorbed from the gastrointestinal tract and, to some extent, through the skin. A dose as small as 1 mg can cause prolonged coagulopathy (4). By inhibiting vitamin K 2,3-epoxide reductase enzyme in the liver, superwarfarins block carboxylation of vitamin K-dependent factors (II, VII, IX, and X) (1). The anticoagulant effect may persist from several days to months, even long after brodifacoum cannot be detected in the blood (5) .
Brodifacoum poisoning is mostly accidental. However, it can result from suicide attempts, industrial exposure, surreptitious ingestion by malingerers (6), or deliberate self-poisoning with denial (Munchausen syndrome) (1) . Bleeding is the most common clinical feature and may occur from any mucosal site or organ (1, 4, 7) . Laboratory studies show elevated prothrombin time and activated partial thromboplastin time that correct on a mixing study; depleted levels of vitamin K-dependent coagulation factors (II, VII, IX, and X); a very high ratio of vitamin K 1 epoxide to reduced vitamin K 1 (8) ; presence of superwarfarin in the blood on special assays, such as high-performance liquid chromatography (4, 9, 10); and undetectable warfarin levels. Prothrombin time and INR may be normal up to 48 hours after exposure. Factor assays (II, VII, IX, and X) may be abnormal in patients with a normal prothrombin time and activated partial thromboplastin time and may provide earlier evidence of significant ingestion. Gastric lavage is not recommended because of increased risk for gastric bleeding. Blood products are used to control active bleeding. Vitamin K 1 (phytonadione) is the specific antidote; menadione (vitamin K 3 ) should not be used (7) . Vitamin K 1 can be given orally, subcutaneously, or intravenously. The daily maintenance dose may vary from 20 mg to 200 mg depending on the severity of coagulopathy (3, 11, 12) , and duration of treatment with vitamin K 1 may vary from 2 months to a year (12) . In our patient, the initial short duration of treatment with vitamin K and the recurrence of bleeding clearly show the need for prolonged vitamin K treatment.
Conclusion: Superwarfarin overdose should be suspected as a cause of coagulopathy resistant to treatment with vitamin K and fresh frozen plasma. Megadoses of vitamin K are needed for weeks to months to treat the prolonged coagulopathy.
